ESHG 2026

Date: June 13, 2026June 15, 2026
Type:
Location:
Areas of Interest:
Home breadcrumb-arrow ESHG 2026

Join SOPHiA GENETICS at the European Human Genetics Conference (ESHG) 2026 in Gothenburg, Sweden! Find us at Booth #214, where our experts will be ready to discuss the latest in genomic testing for rare and inherited disease research. 

Explore our newest applications, including enhanced clinical and whole exomes (WES), whole genome sequencing (WGS), and our extended pharmacogenomics solution, all connected through a single sample-to-report workflow with seamless EHR and LIMS integration of the SOPHiA DDM™ Platform linked with Alamut™ Visual Plus. 

Come discover how SOPHiA DDM™ and Alamut™ Visual Plus can support your lab from sample to clinical insight. 

Corporate Session 

Join our Corporate Session as leading European laboratories share practical approaches to scaling genomic workflows across transcriptomics, WES, and WGS, all powered with our SOPHiA DDM™ Platform and Alamut™ Visual Plus. 

Saturday, 13 June | 12:15pm – 1:30pm | Room A6 

Minna Paavola, Clinical Laboratory Geneticist, Turku University Hospital, Finland 
Tobias Bethge, PhD, Molecular Geneticist, Genetica AG, Switzerland 
Gorka Alkorta-Aranburu, PhD, Laboratory Director, Clínica Universidad de Navarra, Spain 
Sevana Yaghoubian, MSc, Senior Director of Product Management, SOPHiA GENETICS 

Add to calendar 

Poster Presentations 

presented by Izabela Matyszczak, PhD, Technical Product Management Expert - Genomic Research at SOPHiA GENETICS  

Sunday, 14 June | 12:45pm to 1:45pm | P20.159.C 

Add to calendar 

presented by Giulia Muzio, PhD, Bioinformatician - Tertiary Analysis at SOPHiA GENETICS 

Sunday, 14 June | 3:45pm to 4:45pm | P15.094.D 

Add to calendar 

Meet the Experts Networking Session 

Join us at our booth to connect with our genomics experts and take part in engaging conversations with peers and industry professionals. 

Saturday, 13 June | 3:45pm to 4:45pm | Booth #214 

Add to calendar

Book a Meeting

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview
Unlocking Insights, Transforming Healthcare
Learn About SOPHiA DDM™ 
SOPHiA DDM™ for Genomics

Oncology 

Rare and Inherited Disorders

Add-On Modules

SOPHiA DDM™ for Radiomics
Unlock entirely novel insights from your radiology images
Learn About SOPHiA DDM™ for Radiomics 
SOPHiA DDM™ for Multimodal
Explore new frontiers in biology and disease through novel insights
Learn About SOPHiA DDM™ for Multimodal
Professional Services
Accelerate breakthroughs with our tailored enablement services
Learn About our Professional Services